Hormonal
ATF3 acts as a master regulator of metabolic homeostasis and oncogenesis, functioning as a context-dependent hub that can either suppress or promote disease states depending on tissue type and cellular stress.
This paper identifies ATF3 as a critical biological switch in metabolism and cancer. While not a direct intervention for humans yet, it suggests that therapies targeting ATF3 induction (like ST32da) or inhibition could treat metabolic disorders and cancers. Current research focuses on how stress signals trigger ATF3 to regulate glucose and fat storage.
Finally, we demonstrate that ATF3 acts as a master regulator of metabolic homeostasis and, therefore, may be an appealing target for the treatment of metabolic dyshomeostasis, immune disorders, and various cancers.
Why this rating
The paper is a review summarizing multiple preclinical studies (mouse models, cell lines); no human clinical trials are reported.
Source
Master Regulator Activating Transcription Factor 3 (ATF3) in Metabolic Homeostasis and Cancer
Hui‐Chen Ku et al. · Frontiers in Endocrinology · 2020
DOI 10.3389/fendo.2020.00556
More from this paper
- ATF3 induction by synthetic agents like ST32da promotes adipocyte browning and inhibits lipogenesis, potentially offering a mechanism to combat obesity.Moderate
- ATF3 plays a dual role in prostate cancer, acting as a tumor suppressor by inhibiting androgen signaling and AKT, but also as an oncogene by promoting cell proliferation and metastasis via SUMOylation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →